AMAG Pharmaceuticals (AMAG) : Analyst Rating Update

AMAG Pharmaceuticals (AMAG) : 4 brokerage houses believe that AMAG Pharmaceuticals (AMAG) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on AMAG Pharmaceuticals (AMAG). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 8 Wall Street Analysts endorse the stock as a Buy with a rating of 2.

AMAG Pharmaceuticals (AMAG) : 7 investment research analysts covering AMAG Pharmaceuticals (AMAG) have an average price target of $46.29 for the near short term. The highest target price given by the Brokerage Firm to the stock is $80 and the lowest target is $27 for the short term. Analysts expect the variance to be within $18.15 of the average price.

AMAG Pharmaceuticals (NASDAQ:AMAG): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $24.02 and $23.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.89. The buying momentum continued till the end and the stock did not give up its gains. It closed at $24.66, notching a gain of 2.58% for the day. The total traded volume was 673,000 . The stock had closed at $24.04 on the previous day.

Also, Brokerage firm Raymond James downgrades its rating on AMAG Pharmaceuticals (NASDAQ:AMAG). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 4, 2016. The company shares have dropped -64.96% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $77.73 and the one year low was seen on May 19, 2016. The 50-Day Moving Average price is $21.99 and the 200 Day Moving Average price is recorded at $23.73.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.